此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

低剂量 Fostemsavir 缓释相对生物利用度研究

2026年11月12日 更新者:ViiV Healthcare

一项分为两部分的随机研究,以评估单次服用 Fostemsavir 600 mg 片剂与两种 Fostemsavir 200 mg 片剂制剂给药后 Temsavir 的相对生物利用度,并评估食物对健康成人参与者所选 Fostemsavir 200 mg 片剂制剂生物利用度的影响

This is a two-part study. Part 1 will evaluate relative bioavailability of temsavir (TMR) following single dose administration of the reference fostemsavir (FTR) compared to two low-dose ER tablet formulations of FTR. In Part 2, the effect of food on the bioavailability of TMR will be assessed on the selected low-dose ER tablet formulation from Part 1.

研究概览

研究类型

介入性

注册 (实际的)

48

阶段

  • 阶段1

扩展访问

可用的 查看扩展访问记录。

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Texas
      • Austin、Texas、美国、78744
        • GSK Investigational Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 50年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • 18 to 50 years of age inclusive.
  • Healthy as determined by the investigator or medically qualified designee.
  • A participant with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator, in consultation with the Medical Monitor, agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Body weight >= 50 kilograms (kg) (110 pounds [lbs.]) for men and >= 45 kg (99 lbs.) for women and body mass index (BMI) within the range 18.5-31.0 kilogram per meter square (kg/m^2) (inclusive).
  • Male participants are eligible to participate if they agree to use contraceptive methods.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: Is a woman of non-childbearing potential (WONCBP). OR Is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective.
  • Capable of giving signed informed consent.

Exclusion Criteria:

  • History or presence of/significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
  • Alanine transaminase (ALT) >1.5x upper limit of normal (ULN).
  • Total bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if total bilirubin is fractionated and direct bilirubin <35%).
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • QT interval corrected for heart rate according to Fridericia's formula (QTcF) >450 millisecond (msec) for males and QTcF>470 msec for females.
  • Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and ViiV/GlaxoSmithKline (GSK) Medical Monitor the medication will not interfere with the study procedures or compromise participant safety.
  • Participation in the study would result in loss of blood or blood products in excess of 500 milliliters (mL) within 56 days.
  • Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
  • Current enrollment or past participation within the last 30 days or five half-lives whichever is longer, before signing of consent in any other clinical study involving an investigational study intervention or any other type of medical research.
  • Presence of hepatitis B surface antigen (HBsAg) [or hepatitis B core antibody (HBcAb)] at screening or within 3 months prior to first dose of study intervention.
  • Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.
  • Positive hepatitis C Ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention.
  • Positive Human immunodeficiency virus (HIV)-1 and -2 antigen/antibody immunoassay.
  • Cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
  • Regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >14 drinks for males or >7 drinks for females.
  • Regular use of known drugs of abuse.
  • Sensitivity to heparin or heparin-induced thrombocytopenia.
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
  • A participant with a history of beta-lactam allergy, regardless of severity/seriousness.
  • A participant with known or suspected active Coronavirus disease-2019 (COVID-19) infection OR contact with an individual with known COVID-19, within 14 days of study enrollment.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Part 1: Treatment sequence ABC

Participants will receive FTR 3×200 mg ER tablets (Treatment A) in Period 1 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 2 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 3.

Fostemsavir tablets will be administered via oral route.

Fostemsavir tablets will be administered via oral route.

实验性的:Part 1: Treatment sequence BCA

Participants will receive FTR 3×200 mg ER tablets (Treatment B) in Period 1 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment A) in Period 3.

Fostemsavir tablets will be administered via oral route.

Fostemsavir tablets will be administered via oral route.

实验性的:Part 1: Treatment sequence CAB

Participants will receive FTR 600 mg ER tablet in Period 1 (Treatment C, reference) followed by FTR 3×200 mg ER tablets (Treatment A) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 3.

Fostemsavir tablets will be administered via oral route.

Fostemsavir tablets will be administered via oral route.

实验性的:Part 1: Treatment sequence ACB

Participants will receive FTR 3×200 mg ER tablets (Treatment A) in Period 1 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 3.

Fostemsavir tablets will be administered via oral route.

Fostemsavir tablets will be administered via oral route.

实验性的:Part 1: Treatment sequence BAC

Participants will receive FTR 3×200 mg ER tablets (Treatment B) in Period 1 followed by FTR 3×200 mg ER tablets (Treatment A) in Period 2 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 3.

Fostemsavir tablets will be administered via oral route.

Fostemsavir tablets will be administered via oral route.

实验性的:Part 1: Treatment sequence CBA

Participants will receive FTR 600 mg ER tablet (Treatment C, reference) in Period 1 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment A) in Period 3.

Fostemsavir tablets will be administered via oral route.

Fostemsavir tablets will be administered via oral route.

实验性的:Part 2: Treatment sequence DE

Participants will receive the selected low-dose formulation of FTR 3 × 200 mg ER tablets in a fasted state (Treatment D) in Period 1 and following a high fat high calorie meal (Treatment E) in Period 2.

Fostemsavir tablets will be administered via oral route.

实验性的:Part 2: Treatment sequence ED

Participants will receive the selected low-dose formulation of FTR 3 × 200 mg ER tablets following a high fat high calorie meal (Treatment E) in Period 1 and in a fasted state (Treatment D) in Period 2.

Fostemsavir tablets will be administered via oral route.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
第 1 部分:血浆浓度-时间曲线下面积 (AUC) 从时间零到替姆沙韦的最后一个可量化时间点 (AUC[0-t])
大体时间:给药前(第 1 天)直至给药后 72 小时
给药前(第 1 天)直至给药后 72 小时
第 1 部分:从时间零外推到替姆沙韦无限时间 (AUC[0-infinity]) 的 AUC
大体时间:给药前(第 1 天)直至给药后 72 小时
给药前(第 1 天)直至给药后 72 小时
第 1 部分:观察到的最大血浆浓度 (Cmax)
大体时间:给药前(第 1 天)直至给药后 72 小时
给药前(第 1 天)直至给药后 72 小时

次要结果测量

结果测量
大体时间
第 1 部分:替沙韦达到 Cmax (Tmax) 的时间
大体时间:给药前(第 1 天)直至给药后 72 小时
给药前(第 1 天)直至给药后 72 小时
第 1 部分:替沙韦的消除半衰期 (T1/2)
大体时间:给药前(第 1 天)直至给药后 72 小时
给药前(第 1 天)直至给药后 72 小时
第 1 部分:替沙韦给药后 12 小时的浓度
大体时间:给药后 12 小时
给药后 12 小时
第 1 部分和第 2 部分:生命体征和临床实验室参数与基线相比具有临床显着变化的参与者人数
大体时间:基线(第 -1 天)至 4 周随访结束
基线(第 -1 天)至 4 周随访结束
第 1 部分和第 2 部分:报告不良事件 (AE) 和严重不良事件 (SAE) 的参与者数量
大体时间:基线(第 -1 天)至 4 周随访结束
基线(第 -1 天)至 4 周随访结束
第 2 部分:替沙韦的 AUC [0-t]
大体时间:给药前(第 1 天)直至给药后 72 小时
给药前(第 1 天)直至给药后 72 小时
第 2 部分:替沙韦的 AUC [0-无穷大]
大体时间:给药前(第 1 天)直至给药后 72 小时
给药前(第 1 天)直至给药后 72 小时
第 2 部分:替沙韦的 Cmax
大体时间:给药前(第 1 天)直至给药后 72 小时
给药前(第 1 天)直至给药后 72 小时

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:GSK Clinical Trials、ViiV Healthcare

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年3月5日

初级完成 (实际的)

2021年7月31日

研究完成 (实际的)

2021年7月31日

研究注册日期

首次提交

2021年2月12日

首先提交符合 QC 标准的

2021年2月12日

首次发布 (实际的)

2021年2月17日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_28May2026.pdf

IPD 共享时间框架

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

IPD 共享访问标准

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅